#United States #Kedrion #Fort Lee, New Jersey #QIVIGY #IVIG therapy

Kedrion Biopharma to be Honored at Premier's Annual Supplier Innovation Celebration

Kedrion Biopharma, a leading player in the biopharmaceutical industry, is set to receive significant recognition during Premier, Inc.'s annual Supplier Innovation Celebration at the upcoming Breakthroughs Conference and Exhibition in 2026. The prestigious event acknowledges outstanding advancements in healthcare technology, and Kedrion's innovative product, QIVIGY®, is primed for the spotlight.

Kedrion Biopharma has made remarkable strides in patient care, particularly for individuals suffering from primary humoral immunodeficiency (PI). QIVIGY, an immune globulin intravenous solution, is a testament to the company's dedication to research and development in this critical area. It has already been approved by the U.S. Food and Drug Administration (FDA) in 2025, marking a pivotal milestone for patients who require IVIG therapy.

Bob Rossilli, Chief Commercial Officer at Kedrion, expressed pride in this recognition, stating, "This acknowledgment emphasizes the dedication of our teams at Kedrion, who have spent over a decade investing in scientific and manufacturing advancements to provide transformative therapy for individuals living with PI." The company's efforts are noticeable through their commitment to integrating innovative science with the quality of care provided to patients.

Developed through Kedrion's global network, QIVIGY has been engineered to meet the evolving needs of patients. In addition to its approved indication for PI, QIVIGY is currently undergoing further clinical studies to explore its potential utility for other populations and health conditions, demonstrating continued commitment to addressing unmet needs in the healthcare sphere.

The Supplier Innovation Celebration, now entering its 15th year, highlights the most innovative healthcare technologies from around the country. With over 600 suppliers participating in the Breakthroughs Conference, this gathering not only showcases cutting-edge advancements but also emphasizes their impact on patient care. A national committee comprising clinicians, medical practitioners, and supply chain professionals assesses each technology's contributions and effectiveness.

Bruce Radcliff, President of Supply Chain Services at Premier, echoed the sentiments of innovation, saying, "Premier acknowledges Kedrion for its commitment to moving healthcare forward. Their newest product is a significant example of our shared mission to enhance healthcare quality and patient outcomes." The partnership between Kedrion and Premier emphasizes the importance of collaboration in striving for improved health services.

The recognition from Premier holds special significance for Kedrion, particularly considering the alignment in philosophy regarding advancing patient care and pioneering healthcare technology. Lynda Bowe, Vice President of Corporate Accounts and Health Systems at Kedrion, highlighted the value of this collaborative relationship, stating, "We appreciate the partnership we've developed with Premier and look forward to continuing to work together to serve patients dependent on IVIG therapy."

Kedrion Biopharma is deeply dedicated to producing plasma-derived therapies for rare and complex conditions, including immunodeficiencies, coagulation issues, and neurological disorders. Employing around 5,400 staff members, the company operates plasma collection centers in both the United States and the Czech Republic. With a diverse range of 39 products available in over 100 countries, Kedrion holds a prominent position in the global landscape of plasma-derived therapeutics.

As Kedrion forges ahead in the medical community, its commitment to fostering innovation and improving patient outcomes will undoubtedly make a difference in countless lives. QIVIGY symbolizes not just a medical advancement, but a promise to continue striving for excellence in therapies for those affected by immunodeficiencies. For more information about Kedrion's initiatives and their revolutionary products, visit Kedrion's website.

About QIVIGY

QIVIGY® is a 10% immune globulin intravenous solution designed for treating adults with primary humoral immunodeficiency. While its therapeutic applications show great promise, the product does carry warnings regarding potential side effects such as thrombosis and renal dysfunction, requiring meticulous monitoring during administration.

Important Safety Information

Patients considering treatment with QIVIGY should be aware of the possible risks and consult healthcare providers for detailed prescribing information. Understanding both the benefits and potential adverse reactions is crucial for anyone considering this innovative therapy.